Drugs that lack single-agent activity: are they worth pursuing in combination?

被引：26
|
作者：
Gyawali, Bishal [1 ]
Prasad, Vinay [2 ,3 ,4 ]
机构：
[1] Nobel Hosp, Dept Haematooncol, Kathmandu 21034, Nepal
[2] OSHU, Div Hematol Oncol, Knight Canc Inst, Portland, OR 97239 USA
[3] OSHU, Dept Publ Hlth & Prevent Med, Portland, OR 97239 USA
[4] Ctr Eth Hlth Care, 3181 South West Sam Jackson Pk Rd, Portland, OR 97239 USA
来源：
NATURE REVIEWS CLINICAL ONCOLOGY | 2017年 / 14卷 / 04期
关键词：
METASTATIC BREAST-CANCER; MULTIPLE-MYELOMA; TRIAL; MULTICENTER; DOXORUBICIN; BORTEZOMIB;
D O I：
10.1038/nrclinonc.2017.27
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Over the past decade, many anticancer drugs have been approved for use only in combination regimens and only in palliative settings, despite having negligible single-agent activity in the same disease. We examine whether these agents provide any tangible clinical benefits and are worthy of continued development, or whether R&D efforts would be better focused elsewhere.
引用
收藏
页码：1 / 2
页数：2
相关论文
共 50 条
12345